Benign and Malignant Diseases of the Prostate

  • Peter C. Albertsen


Benign prostatic hyperplasia (BPH) and prostate cancer are two of the most common neoplastic growths that occur in elderly men. Both of these conditions are rare before age 50 years, but by age 80 more than 80% of men have evidence of BP hyperplasia histology and more than 50% have at least microscopic foci of prostate cancer.1,2 This chapter reviews the incidence of these two diseases of the prostate, the appropriate evaluation of elderly men, surgical alternatives available to the geriatric patient, and the risks associated with these treatment alternatives.


Prostate Cancer Benign Prostatic Hyperplasia Radical Prostatectomy Gleason Score International Prostate Symptom Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474.PubMedGoogle Scholar
  2. 2.
    Gaynor ER Zur frage des prostatakrebes. Virchows Arch Pathol Anat 1938;301:602–652.CrossRefGoogle Scholar
  3. 3.
    Arrighi HM, Guess HA, Metter EJ, et al. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990;16:253.PubMedCrossRefGoogle Scholar
  4. 4.
    Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973–1995, SEER program, NIH Pub No. 99–4543. Bethesda: National Cancer Institute, 1999.Google Scholar
  5. 5.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 2000;50:7–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards CN, Steinthorsson E, Nicholson D. An autopsy study of latent prostatic cancer. Cancer 1953;32:498–506.Google Scholar
  7. 7.
    Halpert B, Sheehan EE, Schmalhorst WR, Scott R. Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 1963;16:737–742.PubMedCrossRefGoogle Scholar
  8. 8.
    Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963–966.PubMedCrossRefGoogle Scholar
  9. 9.
    Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982;29:611–616.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371–1374.PubMedCrossRefGoogle Scholar
  11. 11.
    Steinberg GS, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337–340.PubMedCrossRefGoogle Scholar
  12. 12.
    McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340.PubMedGoogle Scholar
  13. 13.
    Caine M, Schuger L. The “Capsule” in Benign Prostatic Hypertrophy. NIH Publ No. 87–2881. Bethesda: US Department of Health and Human Services, 1987:221.Google Scholar
  14. 14.
    Byar DP, Mostofi FK. Veterans Administration Cooperative Urologic Research Groups: carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer 1972;30:5–13.PubMedCrossRefGoogle Scholar
  15. 15.
    McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258–266.PubMedCrossRefGoogle Scholar
  16. 16.
    Gleason DF, Mellinger GT. Veterans Administration Cooperative Urological Research Group: prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974;111:58–64.PubMedGoogle Scholar
  17. 17.
    McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline Number 8. AHCPR Publ No. 94–0582. Rockville, MD: Agency for Health Care Policy & Research, Public Health Service, US Department of Health and Human Services, 1994.Google Scholar
  18. 18.
    Mebust WK, Holtgrewe HL, Cockette ATK, Peters PC, Writing Committee. Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989;141:243–247.PubMedGoogle Scholar
  19. 19.
    Melchoir J, Valk WL, Foret JD, Mebust MK. Transurethral prostatectomy in the azotemic patient. J Urol 1974;112: 643–646.Google Scholar
  20. 20.
    Gilliland F, Becker TM, Smith A, et al. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biol Prev 1994;3:105–111.Google Scholar
  21. 21.
    Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;52:1520–1525.Google Scholar
  22. 22.
    Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860–864.PubMedCrossRefGoogle Scholar
  23. 23.
    Benson MC, Whang IS, Olsson CA, et al. Use of prostate specific antigen density to enhance predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817–821.PubMedGoogle Scholar
  24. 24.
    Carter HB, Pearson JD, Metter JE, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215–2220.PubMedCrossRefGoogle Scholar
  25. 25.
    Catalona WJ, Simth DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274: 1214–1220.PubMedCrossRefGoogle Scholar
  26. 26.
    Albertsen PC, Hanley JA, Harlan JC, et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population-based analysis. J Urology 2000;163:1138–1143.CrossRefGoogle Scholar
  27. 27.
    Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based testing. JAMA 1993;270: 948–954.PubMedCrossRefGoogle Scholar
  28. 28.
    Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75–79.PubMedCrossRefGoogle Scholar
  29. 29.
    Johansson JE, Homberg L, Johansson S, Bergstrom R, Adami HO. Fifteen year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277: 467–471.PubMedCrossRefGoogle Scholar
  30. 30.
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242–248.PubMedCrossRefGoogle Scholar
  31. 31.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626–631.PubMedCrossRefGoogle Scholar
  32. 32.
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–980.PubMedCrossRefGoogle Scholar
  33. 33.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127–132.PubMedCrossRefGoogle Scholar
  34. 34.
    Lu-Yao GL, Albertsen PC, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy: a population-based study Urology 1999;54:301–307.Google Scholar
  35. 35.
    Young HH. The early diagnosis and radical cure of carcinoma of the prostate: being a study of 40 cases and presentation of a radical operation which was carried out in four cases. Johns Hopkins Hosp Bull 1905;16:315–321.Google Scholar
  36. 36.
    Fowler FJ, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. J Urol 1993;149:622–629.Google Scholar
  37. 37.
    Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical retropubic prostatectomy. J Urol 1996;156:1707–1713.PubMedCrossRefGoogle Scholar
  38. 38.
    Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of reservation of neurovascular bundles. J Urol 1991;145:998–1002.PubMedGoogle Scholar
  39. 39.
    Murphy GP, Mettlin C, Menck H, et al. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Committee on Cancer. J Urol 1994;152:1817–1819.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Peter C. Albertsen

There are no affiliations available

Personalised recommendations